Major Autohemotherapy (MAHT)
MAHT is the most important form of low-risk systemic ozone application.
The ozone and blood reaction takes place outside of the patient’s body, after which his or her own blood is re-infused with it’s activated red blood cells and activated immunocompetent cells.
50-150 ml of the patient’s blood is withdrawn, and enriched with an exactly dosed quantity of ozone outside of the body. The ozone is then passed through the blood in the form of extremely fine bubbles and the freshly ozonated blood is then administered back to the patient via normal infusion.
The most important indications for MAHT (Major Autohemotherapy) treatments are: arterial circulatory disorders, systemic infections, and diseases occurring in the context of immune deficiencies, e.g. rheumatism/arthritis, lupus, systemic candida, etc.
The the duration of the Major Autohemotherapy (MAHT) treatment procedure is generally around 45 minutes.
| Major autohemotherapy as an extracorporeal blood treatment and intravenous reinfusion of the patients own blood. | Arterial circulatory disorders | Activation of red blood cell metabolism with increase of 2,3-DPG and ATP plus resultant improvement in O2-release |
| Infections, Immunoactivation, additive therapy in carcinoma patients, geriatric field |
Activation of immunocompetent cells with release of cytokins, such as Interferons and Interleukins. | |
| Rheumatic arthritis | Modulation of immune system with increase of IFN-ß, TGF-ßIncrease of the antioxidative capacity by activation of SOD, GSHPx, Catalase … |